SCHEMBL223764

SCHEMBL223764

CC(CC#N)C(Br)(Br)C#N

nearest known ligand 0.32

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5484514 0.98 TSHR (0.31) TSHR
SCHEMBL27513560 0.77
SCHEMBL8384648 0.76 LMNA (0.36)
SCHEMBL8895999 0.76 PBRM1 (0.35)
SCHEMBL28101820 0.72 TSHR (0.33) TSHR
SCHEMBL7632575 0.72 TSHR (0.33) TSHR
SCHEMBL15247260 0.70
SCHEMBL19200939 0.70
SCHEMBL17073925 0.70
SCHEMBL28555639 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1966 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250387489-A1 METHOD FOR PROVIDING A TOPICAL FORMULATION BASE PEEP CLUB LTD (GB) 2025-12-25 US claimed
US-20250332211-A1 COMPOSITIONS FOR INHIBITING DEGRADATION OF HYALURONIC ACID AND METHODS OF USE THEREOF EPIDARUS THERAPEUTICS LLC (US) 2025-10-30 US claimed
US-12370231-B2 Compositions for inhibiting degradation of hyaluronic acid and methods of use thereof EPIDARUS THERAPEUTICS, LLC (US) 2025-07-29 US claimed
EP-4565646-A2 AQUEOUS SALT-FREE STABLE FLUID SUSPENSION COMPOSITIONS AND A METHOD OF PREPARATION THEREOF Hercules LLC (US) 2025-06-11 EP claimed
CN-112294975-B Contact allergen reagent combination and uses thereof 上海市皮肤病医院 2025-01-24 CN claimed
WO-2024102364-A1 SYSTEM AND METHOD FOR REMOTE SCREENING AND DIAGNOSIS OF CONTACT ALLERGIES THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2024-05-16 WO claimed
US-20240148635-A1 COSMETIC COMPOSITIONS COMPRISING POLYETHER POLYMERS P2 SCIENCE, INC. 2024-05-09 US claimed
WO-2024030783-A2 AQUEOUS SALT-FREE STABLE FLUID SUSPENSION COMPOSITIONS AND A METHOD OF PREPARATION THEREOF HERCULES LLC (US) 2024-02-08 WO claimed
US-11883453-B2 Formulation based on medicinal plant, or part or extract thereof, use of the formulation and product including said formulation PHYTOPLENUS BIOATIVOS S.A (BR) 2024-01-30 US claimed
US-11872300-B2 Cosmetic compositions comprising polyether polymers P2 SCIENCE, INC. (US) 2024-01-16 US claimed
EP-1221313-A9 Salts of undecylenoyl glutamate or of undecylenoyl hydrolyzate of wheat or rice proteins in detergent or cosmetic compositions Zschimmer & Schwarz Italiana S.p.A. (IT) 2003-01-02 EP claimed
EP-1221313-A2 Salts of undecylenoyl glutamate or of undecylenoyl hydrolyzate of wheat or rice proteins in detergent or cosmetic compositions Zschimmer & Schwarz Italiana S.p.A. (IT) 2002-07-10 EP claimed
US-20020028754-A1 Antimicrobial compositions NOVOZYMES A/S (DK) 2002-03-07 US claimed
WO-2002008377-A1 ANTIMICROBIAL COMPOSITIONS NOVOZYMES A/S (DK) 2002-01-31 WO claimed
EP-0766557-B1 TOPICAL COMPOSITIONS COMPRISING N-ACETYL-L-CYSTEINE PROCTER & GAMBLE (US) 2001-12-19 EP claimed
CN-1070699-C Topical compositions comprising N-acetyl-L-cysteine PROCTER & GAMBLE (US) 2001-09-12 CN claimed
US-6231849-B1 HUNTING Schiller, George A. 2001-05-15 US claimed
EP-1074247-A2 Cleansing or cosmetic compositions comprising zinc alkylsulphates and/or alky(poly)ethoxysulphates as surfactants and preservatives Zschimmer & Schwarz Italiana S.p.A. (IT) 2001-02-07 EP claimed
US-5716635-A Plantago major transdermal patch for use in treating a tobacco or nicotine habit M. E. CODY PRODUCTS, INC. (US) 1998-02-10 US claimed
EP-0598412-A2 Skinprotection composition MEDICON GESELLSCHAFT FÜR UNTERNEHMENSBERATUNG IM BEREICH MEDIZIN UND GESUNDHEITSWESEN mbH (DE) 1994-05-25 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240148635-A1 COSMETIC COMPOSITIONS COMPRISING POLYETHER POLYMERS CUTA, LAGE3, POLR1C TSHR 2071/4885
US-11872300-B2 Cosmetic compositions comprising polyether polymers CUTA, LAGE3, POLR1C TSHR 2071/4885
US-20250387489-A1 METHOD FOR PROVIDING A TOPICAL FORMULATION BASE VEGFA, AQP3, DSG1 TSHR 3688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.